LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape.
This week in medtech deals over $326.2 million in funding was raised across seven deals, in addition to a number of other undisclosed deals that were announced. Here are some of the top deals tracked:
Start a Free Trial to Medtech Startup Tracker Today
Top Deals – Medtech Fundraising Transactions for the Week
|
Company |
Type |
Amount Raised |
Round |
|
Wearable insulin delivery system |
$115,000,000 |
Series C |
|
|
Memic Innovative Surgeries |
Robotic surgery system |
$96,000,000 |
Series D |
|
1upHealth |
Electronic health data platform |
$25,000,000 |
Series B |
Top deals for the week are based on publicly available information. At this time of this article’s publication, new deals for the week may have been announced.
LSI's Medtech Startup Tracker is focused exclusively on covering the privately-held innovators changing the medical device landscape. Here are some of the interesting startups we’ve recently profiled:
CeQur closes massive $115M Series C roundThe company’s flagship product, CeQur Simplicity, is a discreet, convenient, and injection-free insulin delivery system. The patch-like device, which can be worn for up to 3 days, holds up to 200 units of rapid-acting insulin. With the completion of this latest round of funding, the company has raised to-date an estimated $272M in capital. CeQur plans to utilize the funds from the Series C round to accelerate the commercial launch for its FDA-cleared device. Insulet, Tandem Diabetes, and Ypsomed are some of the key strategics in the diabetes management device market.
CeQur is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
FIZE Medical raises $5.8M for real-time renal monitoring platform
Funds from the round will be used to develop and commercialize the company’s iUO platform. The device is a cost-effective, automatic, digital device that gives healthcare providers access to real-time monitoring of urine output. The iUO device is the base model that FIZE Medical is developing, with the more advanced and feature-rich iUO PLUS and iUO DUOFLO giving providers new capabilities, inludingr acute kidney injury monitoring, shock prediction, and intraabdominal pressure monitoring (IAP). Key competitors in the patient monitoring devices market include Draeger, Philips, and the startup Potrero Medical (a presenting company at LSI’s 2021 Emerging Medtech Summit).
Moray Medical is developing a robotic delivery system for valve repair
Moray Medical’s goal is to simplify the delivery of vascular therapies via its robotics platform. The Coral System is the company’s first product, which combines robotic coordination, augmented reality (AR), and microfluidics into a device that enables transcatheter edge-to-edge repair of the mitral valve. Moray Medical recently announced the completion of its first round of funding, a Seed round which raised $5.7M. The robotic surgery market continues to propel forward as startups and major strategics like Intuitive Surgical, Auris Health (J&J) and Medtronic bring robotic solutions into the hands of surgeons.
SentiAR raises $5.1M from Series A round
The company is developing a fully-controllable, hands-free, augmented reality system for use during complex electrophysiology procedures for the treatment of cardiac arrhythmias. A 3D visualization of the patient’s actual anatomy is generated over the patient to provide clinicians with new insights, improve procedure accuracy, and shorten procedure times. To-date, SentiAR has raised approximately $15M in capital. The closing of the Series A round follows the news that SentiAR obtained FDA clearance for its CommandEP AR system in September 2020.
SentiAR is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Memic Innovative Surgery begins commercialization of robot-assisted surgical system
In March 2021, the company received FDA De Novo Marketing Authorization for its Hominis surgical robotic system. The Hominis system is indicated for use in single-site, transvaginal benign surgical procedures, including hysterectomy. Beyond its initial indication for use, the company plans to pursue approval for use in general surgery and transluminal procedures. In April 2021, the company announced that it had completed a Series D funding round which raised an estimated $96M. Funds from the round will be used to advance commercialization of the Hominis Surgical System in the US and other countries.
Synergia Medical – utilizing optoelectronics for personalized neurostimulation
Synergia is looking to disrupt the neurostimulation market, which has traditionally relied on pacemaker-like devices and wire leads, with its fiber optic-based device that converts optical energy into electrical impulses. While the company’s technology could be used for the treatment of a wide-variety of neurological disorders, Synergia is prioritizing the treatment of epilepsy. According to the company, 30% of all epilepsy patients can not be treated with anti-epileptic drugs, creating a major unmet need and unique opportunity for neurostimulation technologies. Key strategics in the neuromodulation devices market include Abbott, Boston Scientific, and Neuropace.
Synergia Medical is a presenting company at Life Science Intelligence’s 2021 Emerging Medtech Summit.
Learn about the hottest venture funded startups developing innovative medical technologies using Life Science Intelligence’s Medtech Startup Tracker.
Schedule an exploratory call
Request Info© 2024 Life Science Intelligence, Inc., All Rights Reserved. | Privacy Policy
